Back

Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial

28 August 2017 (11:18 - 11:28)
Organised by:
Congress Presentation Part of: Hot Line: Late-Breaking Clinical Trials 2 Atrial fibrillation (AF) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Michael Ezekowitz

Thomas Jefferson University Hospital, Philadelphia (United States of America)

17 More presentations in this session

Presentation thumbnail
SPYRAL HTN OFF-MED Study
Professor M. Boehm (Homburg, DE)
Slides Video
Presentation thumbnail
Discussant review: SPYRAL HTN OFF-MED Study
Professor B. Williams (London, GB)
Slides Video
Presentation thumbnail
Panel discussion.
Presentation thumbnail
Discussant review:Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial
Professor J. Nielsen (Aarhus, DK)
Slides Video
Presentation thumbnail
Panel discussion.

Access the full session

Session thumbnail
Hot Line: Late-Breaking Clinical Trials 2

The Event

Event poster

ESC Congress 2017

28 August 2017 11:18 CET
You may be interested in
thumbnail
Congress Presentation
AF-CARE: “R” Rate and rhythm control
1 September 2024
thumbnail
Congress Presentation
Apixaban versus Warfarin in Patients with Left Ventricular (LV) Thrombus, a prospective randomized trial
28 August 2020
thumbnail
Webinar
Are NOACs already outdated? New trends in anticoagulation therapy
12 December 2022
thumbnail
Congress Presentation
Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials
1 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources